Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice

Antisense and Nucleic Acid Drug Development

Volumn 12, Issue 6, 2002, Pages 359-367

  Wacheck, Volker ^a   Krepler, Clemens ^a   Strommer, Sabine ^a   Heere Ress, Elisabeth ^a   Klem, Robert ^b   Pehamberger, Hubert ^a   Eichler, Hans Georg ^a   Jansen, Burkhard ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Genta Incorporated   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYTOSINE; G 4232; INTERLEUKIN 12; OBLIMERSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN BCL 2; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BOLUS INJECTION; CANCER INHIBITION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; DRUG ACTIVITY; DRUG INFUSION; DRUG MECHANISM; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MALE; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN MOTIF; SCID MOUSE; SPLEEN WEIGHT; SPLENOMEGALY; TUMOR CELL; TUMOR GROWTH; XENOTRANSPLANTATION;

ANIMALIA;

EID: 0036975955     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729002321082438     Document Type: Article

References (20)

1. BALLAS, Z.K., KRIEG, A.M., WARREN, T., RASMUSSEN, W., DAVIS, H.L., WALDSCHMIDT, M., and WEINER, G.J. (2001). Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167, 4878-4886.
2. BOSMA, M.J., and CARROLL, A.M. (1991). The SCID mouse mutant: Definition, characterization, and potential uses. Annu. Rev. Immunol. 9, 323-350.
3. BRUNDA, M.J., LUISTRO, L., RUMENNIK, L., WRIGHT, R.B., DVOROZNIAK, M., AGLIONE, A., WIGGINTON, J.M., WILTROUT, R.H., HENDRZAK, J.A., and PALLERONI, A.V. (1996). Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol. 38 (Suppl), S 16-21.
4. CARPENTIER, A.F., CHEN, L., MALTONTI, F., and DELATTRE, J.Y. (1999). Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59, 5429-5432.
5. CHAO, D.T., and KORSMEYER, S.J. (1998). Bcl-2 family: Regulators of cell death. Annu. Rev. Immunol. 16, 395-419.
6. COTTER, F.E., WATERS, J., and CUNNINGHAM, D. (1999). Human Bcl-2 antisense therapy for lymphomas. Biochim. Biophys. Acta 1489, 97-106.
7. HARTMANN, G., KRUG, A., WALLER-FONTAINE, K., and ENDRES, S. (1996). Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: Dependence on phosphorothioate modification and reversal by heparin. Mol. Med. 2, 429-438.
8. HENDRZAK, J.A., and BRUNDA, M.J. (1995). Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab. Invest. 72, 619-637.
9. JANSEN, B., SCHLAGBAUER-WADL, H., BROWN, B.D., BRYAN, R.N., VAN ELSAS, A., MULLER, M., WOLFF, K., EICHLER, H.G., and PEHAMBERGER, H. (1998). Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4, 232-234.
10. JANSEN, B., WACHECK, V., HEERE-RESS, E., SCHLAGBAUER, WADL, H., HOELLER, C., LUCAS, T., HOERMANN, M., HOLLENSTEIN, U., WOLFF, K., and PEHAMBERGER, H. (2000). Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356, 1728-1733.
11. KLASA, R.J., BALLY, M.B., NG, R., GOLDIE, J.H., GASCOYNE, R.D., AND WONG, F.M. (2000). Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res. 6, 2492-2500.
12. KRIEG, A.M., HARTMANN, G., and YI, A.K. (2000). Mechanism of action of CpG DNA. Curr. Top. Microbiol. Immunol. 247, 1-21.
13. KRIEG, A.M., YI, A.K., and HARTMANN, G. (1999). Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol. Ther. 84, 113-120.
14. KRUG, A., TOWAROWSKI, A., BRITSCH, S., ROTHEN-FUSSER, S., HORNUNG, V., BALS, R., GIESE, T., ENGELMANN, H., ENDRES, S., KRIEG, A.M., and HARTMANN, G. (2001). Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 31, 3026-3037.
15. PAWLAK, W., ZOLNIEREK, J., SAROSIEK, T., and SZCZYLIK, C. (2000). Anfisense therapy in cancer. Cancer Treat. Rev. 26, 333-350.
16. PRATESI, G., PEREGO, P., and ZUNINO, F. (2001). Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy. Biochem. Pharmacol. 61, 381-386.
17. REED, J.C. (2001). Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. 7, 314-319.
18. TAMM, I., DORKEN, B., and HARTMANN, G. (2001). Antisense therapy in oncology: New hope for an old idea? Lancet 358, 489-497.
19. WATERS, J., CLARKE, P.A., CUNNINGHAM, D., MILLER, B., WEBB, A., CORBO, M., and COTTER, F.E. (2000). Bcl-2 antisense oligodeoxynucleotide (ODN) (G3139) therapy exerts its anti-tumour action through a sequence-specific antisense effect, and not a cell-mediated immune response. Proc. Am. Soc. Clin. Oncol. 19, 48 (abstract).
20. ZHAO, Q., TEMSAMANI, J., ZHOU, R.Z., and AGRAWAL, S. (1997). Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7, 495-502.